NEW
HAVEN, Conn., June 17,
2024 /PRNewswire/ -- Wren Laboratories, a leader in
novel in-vitro diagnostic (IVD) technologies, announced today
significant enhancements to its executive leadership team. These
changes aim to strengthen Wren's commercial operations and expand
its market presence as part of the company's ongoing strategy to
foster growth and innovation in diagnostic solutions. While
extending its current standard-of-care testing, Wren Laboratories
now expands services to Biopharma with AI/ML liquid biopsy genomic
assays for translational research and companion diagnostics (CDx)
development. Since 2014, Wren has been enhancing precision medicine
by harnessing data and Al for healthcare excellence to provide
physicians with valuable insights in cancer diagnostics and disease
monitoring. Leveraging their CLIA-certified, CAP-accredited,
and New York State-licensed
clinical laboratory, Wren is set to deliver unparalleled precision
and reliability in diagnostic innovation.
![Wren Laboratories announces enhanced executive team. Wren Laboratories announces enhanced executive team.](https://mma.prnewswire.com/media/2439436/Wren_Laboratories_Logo.jpg)
Wren Laboratories set to deliver
unparalleled precision and reliability in diagnostic
innovation
Dr. Abdel Halim, PharmD, PhD now leads
Wren Laboratories as Chief Executive Officer and Chief Scientific
Officer, bringing an exceptional blend of biotech leadership and
strategic growth expertise. Renowned for his visionary
approach, Dr. Halim is poised to propel Wren into a new era of
innovation and operational excellence. Under his guidance, Wren
will not only amplify its diagnostic capabilities but also achieve
unprecedented efficiency in its operations.
Dr. Halim stands out as one of only four lab professionals in
the USA who holds triple-board
certifications in Molecular Diagnostics, Clinical Chemistry, and
Toxicology; being one of only two people accredited by the FDA
as a third-party reviewer of the largest list of 510(K) submissions
in all classes of IVDs underscores his pivotal role in shaping the
future of biomarkers and precision medicine. His credentials are
further distinguished by his licensure and recognition as
a CLIA clinical lab director across
all 50 states, including NY, NJ, FL, and
TN, encompassing several specialized fields.
Dr. Halim directed the biomarker, translational
research, and precision medicine aspects for 150+ Phase I-III
clinical trials and has a track record for multiple drug and
diagnostic approvals.
Troy Tremaine,
MBA joins Wren's executive leadership team as Senior Vice
President and Chief Commercial Officer. Tremaine brings over 28
years of distinguished experience in the Life Sciences,
Diagnostics, and Contract Research Organization (CRO) industries.
His extensive background includes fostering strategic partnerships,
implementing customer-centric programs, and scaling complex
businesses. Renowned for his dynamic commercial strategies and
profound industry insights, Tremaine will oversee Wren's global
sales, marketing, and customer engagement initiatives. His
leadership is expected to drive Wren's growth and enhance its
market presence.
Dr. Mark Kidd, PhD
DABCC, from Yale University School of
Medicine, continues as Scientific Director, and brings over
20 years of molecular and cancer biology laboratory experience,
with a focus on oncology. As a leading researcher in Neuroendocrine
Tumor (NET) disease, Dr. Kidd has contributed extensively to the
field through diverse publications on tumor biology, global gene
analysis, and molecular diagnostics. He also serves as the CAP- and
CLIA-certified Laboratory Director leading efforts to
advance diagnostic technologies and developing innovative
tumor detection approaches. Dr. Kidd will direct Wren's research
and development efforts, focusing on advancing Wren's proprietary
technologies and product pipeline.
Dr. Eva Szarek,
PhD steps into the role of Head of Marketing. With a PhD
in Molecular Biology from the University of Adelaide, Australia, a postdoctoral fellowship
at the National Institutes of Health, and over 15 years of
experience in the biopharmaceutical industry, Dr. Szarek brings
deep expertise in digital innovation and content
strategy. In her role, Dr. Szarek is expected to significantly
boost Wren's brand visibility and stakeholder engagement.
Melissa Ferone joins
as Director of Quality Assurance, overseeing the quality management
system (QMS) to ensure compliance with CLIA, CAP, NYSDOH, ISO, and
FDA guidance. With a strong background in healthcare business
leadership and extensive experience in laboratory sciences and
regulatory compliance, Melissa is committed to maintaining high
standards and meeting industry expectations.
Launch of Prostate Cancer Diagnostic and Monitoring
Test
In addition to the NETest, a liquid biopsy for NETs, offered
since 2014, Wren Laboratories will launch a novel, non-invasive
liquid biopsy, mRNA-based PROSTest for the detection of prostate
cancer and minimal residual disease (MRD). The PROSTest surpasses
PSA in diagnosing and monitoring prostate cancer patients, making
it the most informative test available on the market.
"This is a transformative time for Wren Laboratories," said Dr.
Abdel Halim. "With our stellar team
and significant intellectual property, including over 115 patents,
we are poised not only to improve cancer patient care by providing
tests for the detection of MRD and predicting cancer prognosis and
response to therapeutics but also to help biopharma enhance the
probability of success."
Learn more about Wren's Biopharma services here.
Updated Commercial Strategy
Alongside these leadership changes, Wren Laboratories is also
refining its commercial strategy. The company anticipates a
significant expansion of its product offerings and aims to
strengthen its partnerships within the biopharma, diagnostic, and
healthcare sectors by providing its novel analytically and
clinically validated assays, and through customizing assays to fit
pharma and biotech needs. This strategy aligns with Wren's
commitment to innovation and excellence in improving patient
outcomes and quality of life through advanced diagnostic
solutions.
About Wren Laboratories
At Wren Laboratories, we are dedicated to pushing the boundaries
of diagnostic technology to improve patient care and drug
development using non-invasive blood and saliva samples for unmet
needs. Founded a decade ago by a distinguished Yale Professor, our
company specializes in developing cutting-edge molecular diagnostic
solutions that cater to a global audience. Our products are
designed to provide precise, reliable, and actionable diagnostic
results, supporting the biomarker continuum from clinical trial
development to clinical testing and patient care.
Media Contact
Troy Tremaine; 919-740-5055
ttremaine@wrenlaboratories.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/wren-laboratories-unveils-dynamic-executive-leadership-team-and-2024-commercial-strategy-overhaul-302174128.html
SOURCE Wren Laboratories